Roche to complete $4.3 billion Spark deal as regulators give all clear

ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche plans to complete its $4.3 billion (3.35 billion pounds) takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales.Roche is buying U.S.-based Spark to expand in gene therapy and boost its..